1. Home
  2. ALV vs TGTX Comparison

ALV vs TGTX Comparison

Compare ALV & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Autoliv Inc.

ALV

Autoliv Inc.

HOLD

Current Price

$114.11

Market Cap

8.8B

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$53.99

Market Cap

8.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALV
TGTX
Founded
1953
1993
Country
Sweden
United States
Employees
64100
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.8B
8.5B
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
ALV
TGTX
Price
$114.11
$53.99
Analyst Decision
Buy
Strong Buy
Analyst Count
12
5
Target Price
$134.00
$49.80
AVG Volume (30 Days)
702.9K
2.8M
Earning Date
04-17-2026
05-04-2026
Dividend Yield
3.07%
N/A
EPS Growth
N/A
1746.67
EPS
N/A
0.12
Revenue
N/A
$2,785,000.00
Revenue This Year
$2.10
$49.08
Revenue Next Year
$3.47
$26.69
P/E Ratio
$13.10
$446.04
Revenue Growth
N/A
N/A
52 Week Low
$99.16
$25.37
52 Week High
$132.17
$57.38

Technical Indicators

Market Signals
Indicator
ALV
TGTX
Relative Strength Index (RSI) 37.24 71.20
Support Level $99.80 $28.57
Resistance Level $123.80 $57.38
Average True Range (ATR) 3.20 2.40
MACD -1.13 0.15
Stochastic Oscillator 0.96 68.64

Price Performance

Historical Comparison
ALV
TGTX

About ALV Autoliv Inc.

Autoliv Inc is a developer, manufacturer, and supplier of passive safety systems to the automotive industry with a broad range of product offerings. Its product portfolio includes passive safety systems for commercial vehicles, battery cut-off switches, safety solutions for riders of motorcycles and bikes, airbags (including steering wheels and inflators), seatbelts, etc. Geographically, the group operates in the Americas, Europe, China, and Asia, excluding China, of which the maximum revenue is generated from its business in the Americas.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: